Skip to main content
Erschienen in:

30.09.2017 | PRECLINICAL STUDIES

The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells

verfasst von: Ludovica Taglieri, Giovanna Rubinacci, Anna Giuffrida, Simone Carradori, Susanna Scarpa

Erschienen in: Investigational New Drugs | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Summary

Glioblastoma multiforme is the most common primary malignant brain tumor and its current chemotherapeutic options are limited to temozolomide. Recently, some synthetic compounds acting as inhibitors of kinesin spindle protein Eg5 have shown pronounced antitumor activity. Our group has recently demonstrated that one of these kinesin Eg5 inhibitors, named K858, exerted important antiproliferative and apoptotic effects on breast cancer cells. Since glioblastoma cells usually express high levels of kinesin Eg5, we tested the effect of K858 on two human glioblastoma cell lines (U-251 and U-87) and found that K858 inhibited cell growth, induced apoptosis, reversed epithelial-mesenchymal transition and inhibited migration in both cell lines. We also detected that, at the same time, K858 increased the expression of survivin, an anti-apoptotic molecule, and that the forced down-regulation of survivin, obtained with the specific inhibitor YM155, boosted K858-dependent apoptosis. This indicated that the anti-tumor activity of K858 on glioblastoma cells is limited by the over-expression of survivin and that the negative regulation of this protein sensitizes tumor cells to K858. These data confirmed that kinesin Eg5 is an interesting target for new therapeutic approaches for glioblastoma. We showed that K858, specifically, was a potent inhibitor of replication, an inducer of apoptosis and a negative regulator of the invasive phenotype for glioblastoma cells.
Literatur
1.
Zurück zum Zitat Muller C, Gross D, Sarli V, Gartner M, Giannis A, Bernhardt G, Buschauer A (2007) Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother Pharmacol 59:157–164CrossRefPubMed Muller C, Gross D, Sarli V, Gartner M, Giannis A, Bernhardt G, Buschauer A (2007) Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother Pharmacol 59:157–164CrossRefPubMed
2.
Zurück zum Zitat Liu L, Liu X, Mare M, Dumont AS, Zhang H, Yan D, Xiong Z (2016) Overexpression of Eg5 correlates with high grade astrocytic neoplasm. J Neuro-Oncol 126:77–80CrossRef Liu L, Liu X, Mare M, Dumont AS, Zhang H, Yan D, Xiong Z (2016) Overexpression of Eg5 correlates with high grade astrocytic neoplasm. J Neuro-Oncol 126:77–80CrossRef
3.
Zurück zum Zitat Valensin S, Ghiron C, Lamanna C, Kremer A, Rossi M, Ferruzzi P, Nievo M, Bakker A (2009) KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain? BMC Cancer 9:196CrossRefPubMedPubMedCentral Valensin S, Ghiron C, Lamanna C, Kremer A, Rossi M, Ferruzzi P, Nievo M, Bakker A (2009) KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain? BMC Cancer 9:196CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, Sims PA, Canoll P, Summers MK, Rosenfeld SS, Rich JN (2015) The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med 7:304ra143 Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, Sims PA, Canoll P, Summers MK, Rosenfeld SS, Rich JN (2015) The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med 7:304ra143
6.
Zurück zum Zitat Cioroiu C, Weimer LH (2017) Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep 17:47CrossRefPubMed Cioroiu C, Weimer LH (2017) Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep 17:47CrossRefPubMed
7.
Zurück zum Zitat Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971–974CrossRefPubMed Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971–974CrossRefPubMed
8.
Zurück zum Zitat Sarli V, Huemmer S, Sunder-Plassmann N, Mayer TU, Giannis A (2005) Synthesis and biological evaluation of novel Eg5 inhibitors. Chembiochem 6:2005–2013CrossRefPubMed Sarli V, Huemmer S, Sunder-Plassmann N, Mayer TU, Giannis A (2005) Synthesis and biological evaluation of novel Eg5 inhibitors. Chembiochem 6:2005–2013CrossRefPubMed
9.
Zurück zum Zitat Nakai R, Iida S, Takahashi T, Tsujita T, Okamoto S, Takada C, Akasaka K, Ichikawa S, Ishida H, Kusaka H, Akinaga S, Murakata C, Honda S, Nitta M, Saya H, Yamashita Y (2009) K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res 69:3901–3909CrossRefPubMed Nakai R, Iida S, Takahashi T, Tsujita T, Okamoto S, Takada C, Akasaka K, Ichikawa S, Ishida H, Kusaka H, Akinaga S, Murakata C, Honda S, Nitta M, Saya H, Yamashita Y (2009) K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res 69:3901–3909CrossRefPubMed
10.
Zurück zum Zitat De Iuliis F, Taglieri L, Salerno G, Giuffrida A, Milana B, Giantulli S, Carradori S, Silvestri I, Scarpa S (2016) The kinesin Eg5 inhibitor K858 induces apoptosis but also surviving-related chemoresistance in breast cancer cells. Investig New Drugs 34:399–406CrossRef De Iuliis F, Taglieri L, Salerno G, Giuffrida A, Milana B, Giantulli S, Carradori S, Silvestri I, Scarpa S (2016) The kinesin Eg5 inhibitor K858 induces apoptosis but also surviving-related chemoresistance in breast cancer cells. Investig New Drugs 34:399–406CrossRef
11.
Zurück zum Zitat Tastekin E, Caloglu VY, Puyan FO, Tokuc B, Caloglu M, Yalta TD, Can N, Guler B (2016) Prognostic value of angiogenesis and survivin expression in patients with glioblastoma. Turk Neurosurg 26:484–490PubMed Tastekin E, Caloglu VY, Puyan FO, Tokuc B, Caloglu M, Yalta TD, Can N, Guler B (2016) Prognostic value of angiogenesis and survivin expression in patients with glioblastoma. Turk Neurosurg 26:484–490PubMed
12.
Zurück zum Zitat Clark MJ, Homer N, O’Connor BD, Chen Z, Eskin A, Lee H, Merriman B, Nelson SF (2010) U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet 6:e1000832CrossRefPubMedPubMedCentral Clark MJ, Homer N, O’Connor BD, Chen Z, Eskin A, Lee H, Merriman B, Nelson SF (2010) U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet 6:e1000832CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF, Wikstrand CJ (1981) Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 40:201–229CrossRefPubMed Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF, Wikstrand CJ (1981) Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 40:201–229CrossRefPubMed
14.
Zurück zum Zitat Tang D, Lahti JM, Kidd VJ (2000) Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3 dependent manner during staurosporine-mediated apoptosis. J Biol Chem 275:9303–9307CrossRefPubMed Tang D, Lahti JM, Kidd VJ (2000) Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3 dependent manner during staurosporine-mediated apoptosis. J Biol Chem 275:9303–9307CrossRefPubMed
15.
Zurück zum Zitat Asraf H, Avunie-Masala R, Hershfinkel M, Gheber L (2015) Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the kinesin-5 inhibitor monastrol. PLoS One 10:e0129255CrossRefPubMedPubMedCentral Asraf H, Avunie-Masala R, Hershfinkel M, Gheber L (2015) Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the kinesin-5 inhibitor monastrol. PLoS One 10:e0129255CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Rello-Varona S, Vitale I, Kepp O, Senovilla L, Jemaà M, Metivier D, Castedo M, Kroemer G (2009) Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. Cell Cycle 8:1030–1035CrossRefPubMed Rello-Varona S, Vitale I, Kepp O, Senovilla L, Jemaà M, Metivier D, Castedo M, Kroemer G (2009) Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. Cell Cycle 8:1030–1035CrossRefPubMed
18.
Zurück zum Zitat Koller E, Propp S, Zhang H, Zhao C, Xiao X, Chang M, Hirsch SA, Shepard PJ, Koo S, Murphy C, Glazer RI, Dean NM (2006) Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. Cancer Res 66:2059–2066CrossRefPubMed Koller E, Propp S, Zhang H, Zhao C, Xiao X, Chang M, Hirsch SA, Shepard PJ, Koo S, Murphy C, Glazer RI, Dean NM (2006) Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. Cancer Res 66:2059–2066CrossRefPubMed
19.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
20.
Zurück zum Zitat De Iuliis F, Salerno G, Giuffrida A, Milana B, Taglieri L, Rubinacci G, Giantulli S, Terella F, Silvestri I, Scarpa S (2016) Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation. Tumor Biol 37:2603–2611CrossRef De Iuliis F, Salerno G, Giuffrida A, Milana B, Taglieri L, Rubinacci G, Giantulli S, Terella F, Silvestri I, Scarpa S (2016) Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation. Tumor Biol 37:2603–2611CrossRef
21.
Zurück zum Zitat Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22:2934–2347CrossRefPubMedPubMedCentral Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22:2934–2347CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Georgakilas AG, Martin OA, Bonner WM (2017) p21: A two-faced genome guardian. Trends Mol Med 23:310–319CrossRefPubMed Georgakilas AG, Martin OA, Bonner WM (2017) p21: A two-faced genome guardian. Trends Mol Med 23:310–319CrossRefPubMed
24.
Zurück zum Zitat Yoon MK, Mitrea DM, Ou L, Kriwacki RW (2012) Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40:981–988CrossRefPubMed Yoon MK, Mitrea DM, Ou L, Kriwacki RW (2012) Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40:981–988CrossRefPubMed
25.
Zurück zum Zitat Zhu T, Li X, Luo L, Wang X, Li Z, Xie P, Gao X, Song Z, Su J, Liang G (2015) Reversion of malignant phenotypes of human glioblastoma cells by beta-elemene through beta-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules. J Transl Med 13:356–370CrossRefPubMedPubMedCentral Zhu T, Li X, Luo L, Wang X, Li Z, Xie P, Gao X, Song Z, Su J, Liang G (2015) Reversion of malignant phenotypes of human glioblastoma cells by beta-elemene through beta-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules. J Transl Med 13:356–370CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat He X, Liu Z, Peng Y, Yu C (2016) Micro RNA-181c inhibits glioblastoma cell invasion, migration and mesenchymal transition by targeting TGF-beta pathway. Bioch Biophys Res Commun 469:1041–1048CrossRef He X, Liu Z, Peng Y, Yu C (2016) Micro RNA-181c inhibits glioblastoma cell invasion, migration and mesenchymal transition by targeting TGF-beta pathway. Bioch Biophys Res Commun 469:1041–1048CrossRef
27.
Zurück zum Zitat Yang WH, Su YH, Hsu WH, Wang CC, Arbiser JL, Yang MH (2016) Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation. Oncogene 35:2287–2289CrossRefPubMed Yang WH, Su YH, Hsu WH, Wang CC, Arbiser JL, Yang MH (2016) Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation. Oncogene 35:2287–2289CrossRefPubMed
28.
Zurück zum Zitat Falnikar A, Tole S, Baas PW (2011) Kinesin-5, a mitotic microtubule-associated motor protein, modulates neuronal migration. Mol Biol Cell 22:1561–1574CrossRefPubMedPubMedCentral Falnikar A, Tole S, Baas PW (2011) Kinesin-5, a mitotic microtubule-associated motor protein, modulates neuronal migration. Mol Biol Cell 22:1561–1574CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Wang F, Lin SL (2014) Knockdown of kinesin KIF11 abrogates directed migration in response to epidermal growth factor-mediated chemotaxis. Bioch Biophys Res Commun 452:642–648CrossRef Wang F, Lin SL (2014) Knockdown of kinesin KIF11 abrogates directed migration in response to epidermal growth factor-mediated chemotaxis. Bioch Biophys Res Commun 452:642–648CrossRef
30.
Zurück zum Zitat Sun XD, Shi XJ, Sun XO, Luo YG, Wu XJ, Yao CF, Yu HY, Li DW, Liu M, Zhou J (2011) Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Acta Pharmacol Sin 32:1543–1548CrossRefPubMedPubMedCentral Sun XD, Shi XJ, Sun XO, Luo YG, Wu XJ, Yao CF, Yu HY, Li DW, Liu M, Zhou J (2011) Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Acta Pharmacol Sin 32:1543–1548CrossRefPubMedPubMedCentral
Metadaten
Titel
The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells
verfasst von
Ludovica Taglieri
Giovanna Rubinacci
Anna Giuffrida
Simone Carradori
Susanna Scarpa
Publikationsdatum
30.09.2017
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 1/2018
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0517-1

Neu im Fachgebiet Onkologie

Neue chemotherapiefreie Kombinationstherapie punktet bei CLL

Zwischenergebnisse der Phase-III-Studie AMPLIFY sprechen dafür, dass die zeitlich begrenzte Behandlung mit Acalabrutinib und Venetoclax fitte Personen mit chronischer lymphatischer Leukämie länger leben lässt als eine Chemoimmuntherapie.

NRG1-Fusionen als neues, klinisch relevantes Target

Ergebnisse einer Phase-II-Studie deuten darauf hin, dass ein gegen HER3 und HER2 gerichteter Antikörper bei verschiedenen NRG1-Fusions-positiven Tumoren wirksam sein könnte. In den USA ist die Substanz bereits beschleunigt zugelassen worden.

Die aktuelle S3-Leitlinie zu CLL strotzt vor Neuerungen

Vor kurzem wurde eine neue, grundlegend überarbeite Version der S3-Leitlinie Chronische Lymphatische Leukämie (CLL) veröffentlicht.  Zu den wichtigsten Änderungen gehört, dass die Chemoimmuntherapie auf dem Rückzug ist.

Gluteuslappen nach Rektumkarzinom-Op. schützt vor Abszessen

Die Wunddeckung mit einem autologen Rotationslappen nach Entfernung eines Rektumkarzinoms konnte in einer randomisierten Studie gegenüber dem primären Wundverschluss vor allem in einer Hinsicht punkten: Sie führte deutlich seltener zu präsakralen Abszessen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.